Danaher Corporation(DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Latest News & Analysis
Danaher (DHR): Diagnostics Strength Amidst Life Sciences Challenges
Danaher (DHR) faces headwinds in life sciences but sees strength in diagnostics and Abcam. Cost optimization and shareholder returns are key.
Danaher (DHR): Life Sciences Challenges & Diagnostics Growth
Danaher Corporation (DHR) navigates Life Sciences headwinds with strategic growth in diagnostics, AI, and industrial lasers. A potential buying opportunity arises near its 5-year low.
Danaher (DHR): FDA Clearance, AI Strategy, and Market Outlook
Danaher's strategic moves, including FDA clearance for its DxC 500i analyzer and AI integration, are set against a backdrop of tempered growth forecasts and market volatility.
Danaher Corporation: Dividend Growth and Strategic Financial Update
A deep dive into Danaher's dividend increase, AI board appointment, and market performance driving strategic growth.
Danaher (DHR): Dividend, AI Strategy, and Market Growth Analysis
Danaher's dividend increase, AI strategy, and key market positions drive shareholder value. A comprehensive analysis of DHR's growth and stability.
Danaher (DHR): Dividend, AI, and Market Expansion – A Comprehensive Analysis
Danaher navigates a dynamic market with AI, molecular diagnostics, and laser marking strategies. An increased dividend signals strength. Challenges include market volatility.
Danaher's Strategic Shift: Dividends, AI, and Market Growth
Danaher strategically shifts towards AI, boosts dividends, and targets market growth in diagnostics and laser marking, signaling robust future prospects.
Danaher (DHR): Dividend, AI Strategy, and Market Growth Analysis
Danaher (DHR) balances dividend growth, AI strategy, and market expansion amid volatility. Key is infectious disease testing and laser marking market growth.
Danaher: Dividend Hike, AI Push, and Navigating Market Uncertainty
Explore Danaher's strategic developments including an 18.5% dividend increase and board appointment that drive market impact.
Danaher's Strategic Shift: AI Integration, Dividend Boost
Danaher Corporation (DHR) sees strategic shifts with a new board member, increased dividends, and a strong position in molecular diagnostics.
Danaher Corporation: Navigating Market Challenges in 2025
A comprehensive data-driven analysis of Danaher Corporation’s intraday market performance, earnings, and strategic shifts in 2025.
Danaher Corporation: Strategic Shifts Amid Biotech Headwinds
A forward-looking analysis of Danaher’s strategic moves amid biotech challenges and expanding molecular diagnostics opportunities.